Literature DB >> 14614216

Changes in serum TSH receptor antibody (TRAb) values in patients with Graves' disease after total or subtotal thyroidectomy.

Yuuki Takamura1, Keiichi Nakano, Takashi Uruno, Yasuhiro Ito, Akihiro Miya, Kaoru Kobayashi, Tamotsu Yokozawa, Fumio Matsuzuka, Kanji Kuma, Akira Miyauchi.   

Abstract

TSH receptor antibodies (TRAb) are generally regarded as mediators of thyroid stimulation in Graves' disease. In addition, a high serum TRAb value during pregnancy is one of the risk factors for intrauterine death, prematurity, and fetal or neonatal hyperthyroidism. Recently, correlations between a high serum TRAb value and endocrine opthalmopathy were also suggested. Surgical resection of the thyroid is usually followed by a reduction of serum TRAb levels in variable degrees. The relation between the extent of the thyroidectomy and the degree of reduction is still controversial. In addition, the changes in the TRAb value after total thyroidectomy (TT) over a long period of time have never been studied. We studied the changes in serum TRAb values after TT and subtotal thyroidectomy (ST) for more than 7 years. Forty-one patients with Graves' disease underwent TT, and 99 patients underwent ST. The serum TRAb values and the ratio of the patients who achieved normal values among each group (normalization rates of TRAb) at 3 and 6 months, 1, 3, 5 and 7 years after surgery were compared between the TT group and ST group. The mean preoperative TRAb values were not significantly different between the TT and ST groups, and the mean TRAb values measured 3, 6 and 12 months after surgery were not significantly different between the groups. However, the TRAb values measured 3, 5 and 7 years after surgery were significantly (p<0.05) lower in the TT group than in the ST group (16.7 +/- 3.3% vs 28.0 +/- 2.6%, 12.6 +/- 3.4% vs 29.3 +/- 3.8%, 5.6 +/- 0.9% vs 25.4 +/- 4.1%, respectively). The normalization rates of TRAb were not significantly different between the groups until 1 year after surgery. However, the normalization rates 3, 5 and 7 years after surgery were significantly (p<0.05) higher in the TT group than in the ST group (65.7% vs 42.4%, 77.3% vs 46.7%, 100% vs 59.1%, respectively). The surgical complication rates of TT were similar to ST except for permanent hypoparathyroidism. TT is a treatment option for Graves' disease, especially in patients with a high TRAb value who wish to have children or who have Graves' opthalmopathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614216     DOI: 10.1507/endocrj.50.595

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  8 in total

1.  Clinical features of thyroid-associated ophthalmopathy in clinically euthyroid Korean patients.

Authors:  S Y Jang; S Y Lee; E J Lee; J S Yoon
Journal:  Eye (Lond)       Date:  2012-06-29       Impact factor: 3.775

2.  Long-term outcome of Graves' disease patients treated in a region with iodine deficiency: relapse rate increases in years with thionamides.

Authors:  Neslihan Basçil Tütüncü; Tanju Tütüncü; Ali Ozgen; Tomris Erbas
Journal:  J Natl Med Assoc       Date:  2006-06       Impact factor: 1.798

3.  Does thyroid surgery for Graves' disease improve health-related quality of life?

Authors:  Gregorio Scerrino; Giuditta Morfino; Nunzia Cinzia Paladino; Valentina Di Paola; Emanuele Amodio; Gaspare Gulotta; Sebastiano Bonventre
Journal:  Surg Today       Date:  2012-12-11       Impact factor: 2.549

4.  Different fetal-neonatal outcomes in siblings born to a mother with Graves-Basedow disease after total thyroidectomy: a case series.

Authors:  Antonio Alberto Zuppa; Paola Sindico; Sabrina Perrone; Chiara Carducci; Eleonora Antichi; Giovanni Alighieri; Francesco Cota; Patrizia Papacci; Maria Pia De Carolis; Costantino Romagnoli; Valentina Cardiello
Journal:  J Med Case Rep       Date:  2010-02-19

Review 5.  Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future.

Authors:  Natacha Turck; Simone Eperon; Maria De Los Angeles Gracia; Aurélie Obéric; Mehrad Hamédani
Journal:  Dis Markers       Date:  2018-03-15       Impact factor: 3.434

6.  Persistent hyperthyroidism and de novo Graves' ophthalmopathy after total thyroidectomy.

Authors:  Wei Lin Tay; Wann Jia Loh; Lianne Ai Ling Lee; Chiaw Ling Chng
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2017-10-13

7.  Longitudinal association of thyroid-stimulating immunoglobulin levels with clinical characteristics in thyroid eye disease.

Authors:  JaeSang Ko; Koung Hoon Kook; Jin Sook Yoon; Kyung In Woo; Jae Wook Yang
Journal:  BMJ Open       Date:  2022-06-21       Impact factor: 3.006

8.  Total thyroidectomy as the single surgical option for benign and malignant thyroid disease: a surgical challenge.

Authors:  Ioannis Vassiliou; Aliki Tympa; Nikolaos Arkadopoulos; Fotios Nikolakopoulos; Thalia Petropoulou; Vassilios Smyrniotis
Journal:  Arch Med Sci       Date:  2013-02-18       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.